Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms

Precision medicine approaches such as ex vivo drug sensitivity screening (DSS) are appealing to inform rational drug selection in myelodysplastic syndromes (MDSs) and acute myeloid leukemia, given their marked biologic heterogeneity. We evaluated a novel, fully automated ex vivo DSS platform that us...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Spinner, Michael A., Aleshin, Alexey, Santaguida, Marianne T., Schaffert, Steven A., Zehnder, James L., Patterson, A. Scott, Gekas, Christos, Heiser, Diane, Greenberg, Peter L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2020
Konular:
Myeloid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7322964/
https://ncbi.nlm.nih.gov/pubmed/32569379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001934
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller